1B3O

TERNARY COMPLEX OF HUMAN TYPE-II INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP AND SELENAZOLE ADENINE DINUCLEOTIDE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.244 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Colby, T.D.Vanderveen, K.Strickler, M.D.Markham, G.D.Goldstein, B.M.

(1999) Proc Natl Acad Sci U S A 96: 3531-3536

  • DOI: 10.1073/pnas.96.7.3531
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Inosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step in the regulation of cell growth and differentiation. This step is the NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5' monophosphate, the rate-limiting step in the synthesis of the guanine nucleotides ...

    Inosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step in the regulation of cell growth and differentiation. This step is the NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5' monophosphate, the rate-limiting step in the synthesis of the guanine nucleotides. Two isoforms of IMPDH have been identified, one of which (type II) is significantly up- regulated in neoplastic and differentiating cells. As such, it has been identified as a major target in antitumor and immunosuppressive drug design. We present here the 2.9-A structure of a ternary complex of the human type II isoform of IMPDH. The complex contains the substrate analogue 6-chloropurine riboside 5'-monophosphate (6-Cl-IMP) and the NAD analogue selenazole-4-carboxamide adenine dinucleotide, the selenium derivative of the active metabolite of the antitumor drug tiazofurin. The enzyme forms a homotetramer, with the dinucleotide binding at the monomer-monomer interface. The 6 chloro-substituted purine base is dehalogenated, forming a covalent adduct at C6 with Cys-331. The dinucleotide selenazole base is stacked against the 6-Cl-IMP purine ring in an orientation consistent with the B-side stereochemistry of hydride transfer seen with NAD. The adenosine end of the ligand interacts with residues not conserved between the type I and type II isoforms, suggesting strategies for the design of isoform-specific agents.


    Organizational Affiliation

    Department of Biochemistry and Biophysics, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
PROTEIN (INOSINE MONOPHOSPHATE DEHYDROGENASE 2)A, B514Homo sapiensMutation(s): 0 
Gene Names: IMPDH2IMPD2
EC: 1.1.1.205
Find proteins for P12268 (Homo sapiens)
Explore P12268 
Go to UniProtKB:  P12268
NIH Common Fund Data Resources
PHAROS  P12268
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SAE
Query on SAE

Download CCD File 
A, B
SELENAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE
C19 H25 N7 O14 P2 Se
SKNBJMQZTZPCPF-QZTLEVGFSA-N
 Ligand Interaction
CPR
Query on CPR

Download CCD File 
A, B
6-CHLOROPURINE RIBOSIDE, 5'-MONOPHOSPHATE
C10 H13 Cl N4 O7 P
ALOBOMYIOYNCBS-KQYNXXCUSA-O
 Ligand Interaction
UNX
Query on UNX

Download CCD File 
B
UNKNOWN ATOM OR ION
X
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.244 
  • Space Group: I 4
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 142.26α = 90
b = 142.26β = 90
c = 174.94γ = 90
Software Package:
Software NamePurpose
X-PLORmodel building
CNSrefinement
DENZOdata reduction
SCALEPACKdata scaling
X-PLORphasing
CNSphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 1999-04-12
    Type: Initial release
  • Version 1.1: 2008-04-26
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance